Skip to content
  • About us
    • Overview
    • Our founders
    • Careers
  • Our pipeline
    • Development pipeline
    • Netazepide
      • Background
      • Studies
      • Further studies
    • Ceclazepide
    • TR4
    • TR8
  • Trio Medicines Logo
  • Our publications
  • Contact us
Previous Next

The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.

Sagatun L, Mjønes P, Jianu CS, Boyce M, Waldum HL, Fossmark R. The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.  Eur J Gastroenterol Hepatol; 2016; 28: 1345–1352.

myarzi12019-03-26T13:06:25+00:00Netazepide|

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditGoogle+TumblrPinterestVkEmail